Introduction
Isavuconazole is a new triazole compound with broad-spectrum in vitro activity against Aspergillus species and a range of other medically important yeasts and moulds [1e5] . In 2015 it was licensed for invasive aspergillosis of adults by the EMA [6] and the FDA [7] , following the phase III SECURE trial, which demonstrated non-inferiority compared with voriconazole regarding invasive mould infections [8] . The standard first-line treatment for invasive aspergillosis has until now been voriconazole [9, 10] . Voriconazole has variable pharmacokinetics and a narrow therapeutic window, and as such, a proportion of patients are either under-dosed or experience adverse effects due to toxic levels [11] . Drug interactions can pose a problem, as can the cyclodextrin content of the intravenous formulation when treating patients who have renal impairment. Isavuconazole provides a welcomed expansion of the available armamentarium against mould infections and offers a favourable profile regarding drug interactions, toxicology, pharmacokinetics and with a spectrum at least partially including Mucorales.
Isavuconazole has been shown to be efficacious in oesophageal candidiasis [12] and has been investigated in the phase III clinical ACTIVE trial including patients with proven candidaemia or invasive candidiasis. Data evaluation failed to demonstrate noninferiority compared with caspofungin but did show a similar overall success at the end of treatment, overall mortality and good tolerability (26th European Congress of Clinical Microbiology and Infectious Diseases, abstract 1239). Although these findings support the notion that echinocandins are superior to azoles for the treatment of candidaemia/invasive candidiasis, isavuconazole may remain relevant for selected patients with mixed infections, echinocandin-resistant infections, complicating factors, or for oral step down.
In this study, we investigated the in vitro susceptibility to isavuconazole compared with voriconazole against a large contemporary clinical collection of Aspergillus and Candida isolates received at the Danish mycology reference centre, including azoleresistant isolates. MICs were interpreted using the recently established EUCAST clinical breakpoints and epidemiological cut-off values (ECOFFs).
Materials and methods

Isolates
A total of 958 Aspergillus and 1677 Candida isolates, from 683 and 1487 patients, respectively, were included. The collections contained all isolates from clinical samples or pure cultures received at the mycology reference laboratory at Statens Serum Institut for identification and susceptibility testing during the calendar years 2012e2014. No ethical restraints apply to studies of routinely obtained anonymized laboratory data. Identification was done using macro-and micromorphology, supplemented by thermo-tolerance (incubation at 37 C and 43 C) and matrixassisted laser desorption/ionization time-of-flight mass spectrometry (Bruker, Bremen, Germany) for Candida [13] and by thermotolerance (incubation at 50 C) for Aspergillus fumigatus complex isolates and b-tubulin sequencing [14] for cryptic Aspergillus species. The use of the term 'complex' is acknowledged for Aspergillus species other than A. fumigatus, in the absence of detailed molecular identification, although for simplicity, it is not used throughout this manuscript.
Susceptibility testing
EUCAST susceptibility testing was performed according to E.Def 7.2 for Candida [15] . Voriconazole MIC determination was performed for 1647 of 1677 (98.2%) isolates and isavuconazole MIC determination for all 1677 isolates. For Aspergillus, screening for azole resistance was gradually introduced in routine laboratory practice during the collection period, using an azole containing four-well agar (containing itraconazole: 4 mg/L; voriconazole: 1 mg/L; posaconazole: 0.5 mg/l and an antifungal-free control well (Balis Laboratorium V.O.F., Bowen-Leeuwen, the Netherlands)) [14] .
In brief, 25 mL of a McFarland 0.5 conidial suspension was added to each well and incubated for 48 hours before reading. Hence, EUCAST susceptibility testing [15] was performed for 306 of 958 Aspergillus isolates (227 patients) that grew on at least one of the azole agars, or were non-A. fumigatus isolates. For EUCAST susceptibility testing, stock solutions (5000 mg/L in dimethyl sulphoxide; Sigma-Aldrich, Brøndby, Denmark) of itraconazole (SigmaAldrich), voriconazole (Pfizer, Ballerup, Denmark), posaconazole (MSD, Ballerup, Denmark) and isavuconazole (Basilea Pharmaceutica Ltd., Basel, Switzerland) were prepared. Final drug concentration ranges for isavuconazole and voriconazole were 0.03e4 mg/L for Candida spp. and 0.125e16 mg/L for Aspergillus spp., respectively. MICs were determined spectrophotometrically at 24 hours as the lowest concentration giving a 50% growth reduction compared with an antifungal free control (Candida), or visually applying a nogrowth endpoint after 48 hours of incubation (Aspergillus), as recommended. EUCAST control strains Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were routinely included and read after 24 hours [15] . Except for non-wild-type A. fumigatus isolates, only isavuconazole and voriconazole MICs are presented in this report. For interpretation of susceptibility, the following EUCAST clinical breakpoints were used for A. fumigatus: isavuconazole MIC 1 mg/L (susceptible) and >1 mg/L (resistant); and voriconazole MIC 1 mg/L (susceptible) and >2 mg/L (resistant).
ECOFF/wild-type definitions
Isolates were categorized as wild-type (wt) or non-wild-type (non-wt) adopting the EUCAST ECOFFs. These have been defined for A. fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus terreus and Aspergillus nidulans (voriconazole and isavuconazole) [16, 17] and for Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis and Candida tropicalis (voriconazole) [18] . For yeast species without a defined EUCAST ECOFF, a wild-type upper limit (wtUL) was determined as two two-fold dilution steps above the MIC 50 (MIC 50 value is the lowest concentration of the antifungal at which 50% of the isolates were inhibited) with the exception of species for which the entire population of MICs were less than or equal to the lowest concentration tested. In such cases, the lowest concentration tested was chosen as the wtUL [19] .
The MIC 50 , MIC distribution range and number of isolates with MICs above the ECOFF/wtUL were determined and compared by species and antifungal compound.
PCR amplification and sequence analysis of the CYP51A gene
Isolates of A. fumigatus classified as non-susceptible or non-wt to itraconazole, posaconazole, isavuconazole or voriconazole were CYP51A sequenced as part of the routine procedures (as previously described [20] ), except for one azole-resistant isolate from 2012, which was not available for CYP51A sequencing. Additionally, a few azole-susceptible isolates were sequenced as controls, or if the patient had previously harboured an azole-resistant A. fumigatus. In total, 57 A. fumigatus isolates were CYP51A sequenced, 45 of which had elevated MICs towards isavuconazole or voriconazole.
Nine A. terreus isolates were obtained from one patient with cystic fibrosis known since 2007 to repeatedly harbour isolates with an M217I alteration [21] . Eight of these isolates (one wt and seven resistant) were CYP51A sequenced as previously described [21] .
Results
Isolates and MIC distributions
The normally azole-susceptible Candida species had very low and comparable MIC distributions for both compounds (Table 1 and Fig. 1 ). The following species-specific wtULs for isavuconazole MIC distributions were determined: C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis: 0.03 mg/L; C. glabrata and Saccharomyces cerevisiae: 0.125 mg/L, and C. krusei: 0.25 mg/L. For C. glabrata, C. krusei, S. cerevisiae and other Candida spp., for which the MIC distributions were not truncated, the isavuconazole MIC 50 and wtULs were one or two dilution steps lower than those for voriconazole. The percentage of non-wt isolates for the two compounds (isavuconazole/voriconazole) was as follow: C. albicans (0.8/1.0), C. dubliniensis (0/1.8), C. glabrata (14.9/9.5), C. krusei (2.7/ 1.4), C. parapsilosis (1.7/1.8), C. tropicalis (14.3/19.1) and S. cerevisiae (10.0/0). For voriconazole, the species-specific wtULs defined in this study were at least two dilution steps lower than the EUCAST ECOFFs for all species, with the exception of C. krusei (Table 1) .
For the 306 (32%) Aspergillus isolates that underwent EUCAST susceptibility testing due to a non-fumigatus Aspergillus species identification or growth at the screening agar, the species-specific MIC 50 values for isavuconazole and voriconazole were again within one two-fold dilution step of each other (Table 2) . Hence, the isavuconazole MIC distributions were approximately one dilution step higher for A. fumigatus and A. niger (including A. tubingensis) compared with those for voriconazole and one dilution step lower for A. nidulans. The percentage of MICs above the ECOFFs for the two compounds (isavuconazole/voriconazole) were as follows: A. fumigatus (13.7/15.2); A. niger (4.9/0); A. terreus (48.2/22.2; but 27.8/0 if excluding all isolates from a patient with the previously detected M217I alteration); A. flavus (0/0) and A. nidulans (0/0) (Fig. 2) . Applying the clinical breakpoints for the 26.3% of A. fumigatus isolates that underwent EUCAST susceptibility testing, the susceptibility profiles were as follows: isavuconazole: 78.2% (susceptible; S)/21.8% (resistant; R), voriconazole: 84.8% (S)/6.intermediate; 6% (I)/8.5% (R); overall, 24.2% were found to be nonsusceptible to at least one mould-active azole. The overall isavuconazole and voriconazole non-susceptibility rates among A. fumigatus (when including the 592 isolates found susceptible using the azole agar screenings test) were 5.7% (n ¼ 46) and 4.0% (n ¼ 32), respectively; 6.4% (n ¼ 51) exhibited resistance to at least one mould-active azole. The detailed triazole MIC and CYP51A profile for the individual A. fumigatus and A. terreus isolates with an MIC of 2 mg/L are available in the Supplementary material (Tables S1 and S2 ).
CYP51A sequencing
Thirty-two isolates of A. fumigatus isolates with non-wt MIC values towards voriconazole (n ¼ 31) or isavuconazole (n ¼ 28) were sequenced (Fig. 2) . Isolates with an isavuconazole MIC value of 4 mg/L also had elevated MIC values for voriconazole and/or at least one other triazole. In 25 of these isolates (89.3%), CYP51A mutations known to confer pan-azole resistance were found (M220I þ V101F (n ¼ 3), TR 34 /L98H (n ¼ 10), TR 34 /L98H/S297T/ F495I (n ¼ 4), and TR 46 /Y121F/T289A (n ¼ 8)) (Fig. 2) .
Seventeen isolates had an isavuconazole MIC of 2 mg/L (8.1% of EUCAST susceptibility tested and 2.1% of all A. fumigatus isolates). Five of these (29.4%) also had an elevated MIC value towards one of the other triazoles (see Supplementary material, Table S1 ). Overall, six of the 17 isolates (35.3%) harboured a CYP51A mutation (M220K (n ¼ 1), D262Y (n ¼ 2), F46Y/M172V/E427K (n ¼ 2) and TR 34 /L98H (n ¼ 1)). Five isolates with MICs of voriconazole and isavuconazole 1 mg/L were sequenced due to elevated MICs for posaconazole and itraconazole, four of which harboured G54W (n ¼ 1), P216L (n ¼ 2) or M220K (n ¼ 1) alterations.
A high number of non-wt A. terreus isolates (z50% for isavuconazole) were found (Fig. 2) . One patient with cystic fibrosis contributed with eight resistant isolates and one phenotypically azole-susceptible isolate; all sequenced resistant isolates had the M217I alteration, synonymous with the M220I alteration in A. fumigatus. The phenotypically pan-azole susceptible isolate harboured an Y491H alteration. In A. fumigatus, this alteration has been associated with elevated itraconazole MICs [22] but its significance in A. terreus is unknown. The eight resistant isolates from this patient were all identified as non-wt applying the isavuconazole ECOFF, whereas six were non-wt applying the voriconazole EUCAST ECOFF (see Supplementary material, Table S2 ).
Discussion
Overall, the in vitro activities of isavuconazole and voriconazole against Candida and Aspergillus isolates were comparable and consistent with previously published EUCAST [2] and CLSI [1, 5, 23, 24] MICs. However, for C. krusei and C. glabrata our wt distributions were two to three dilution steps lower than those reported by CLSI, which may reflect the inter-laboratory variability previously associated with MIC testing of these species (C. glabrata especially [2] ).
Elevated MICs were not uncommon. Indeed, up to 15% of C. glabrata and C. tropicalis displayed non-wt MICs for isavuconazole, whereas this was the case for 5.7% of all included A. fumigatus isolates. Reports of azole resistance rates in A. fumigatus vary. In an international surveillance study from 2009 to 2011 the prevalence in Denmark was 3.3% and equal to the overall average [25] . A subsequent retrospective laboratory-based documented an increase in azole resistance from 1.4% to 6% in clinical samples in the time period 2010e2014, suggesting that the resistance rate in Denmark may be increasing [26] .
The proportion of isolates with an isavuconazole MIC of 2 mg/L (categorized as resistant but still within the wt MIC range) was comparable to the proportion reported from a recent multicentre study (~8%; 34/401 isolates), but higher than in the data set used for setting the EUCAST ECOFFS (3%) [2, 17] . This may reflect the selected proportion of isolates undergoing EUCAST susceptibility testing after azole agar screening (for which a higher proportion of resistance is expected) and the fact that isolates received at a reference laboratory constitute a selected subset of isolates that may not be fully representative for the national epidemiology.
All A. fumigatus isolates with CYP51A mutations consistently known to confer voriconazole or pan-azole resistance were classified as resistant applying the isavuconazole breakpoint. One M220K alteration resulted in discreet MIC elevations (isavuconazole MIC of 2 mg/L), but whether this is clinically relevant is unclear. However, one TR 34 /L98H was found within the wt MIC range (isavuconazole MIC of 2 mg/L). In comparison, one TR 34 /L98H/ S297T/F495I was classified as voriconazole susceptible, illustrating that perfect discrimination of susceptible and mutant isolates is challenging to achieve due to the overlapping MIC distributions for wt and mutant isolates for both compounds.
For A. terreus, we found a high proportion of non-wt isolates for both drugs and notably higher (27.8%) for isavuconazole compared with voriconazole (0%), even after excluding a patient known to harbour isolates with an M217I alteration. These differences are most likely not reflecting efficacy differences between the two compounds, but rather technical issues related to MIC testing and categorization, as the MIC distributions were symmetric with an MIC 50 of 1 mg/L and produced an almost identical categorization if an isavuconazole ECOFF of 2 mg/L was applied.
Two A. niger complex isolates (4.9%) were non-wt for isavuconazole, one of which belonged to the intrinsically less susceptible cryptic species A. tubingensis. This is in line with a previous report and within the percentage of wild-type isolates expected to be above the ECOFF [2, 27] .
Technical challenges regarding MIC endpoint reading were encountered. For C. tropicalis, we found a tail of high MIC values for both compounds, primarily consisting of isolates with trailing phenotype, i.e. with residual growth over a broad range of MIC values. Whether such isolates are truly resistant is still unresolved and the phenomenon implies a risk of variation in MIC and random susceptibility classification. Moreover, the growth curves for C. krusei were less steep for isavuconazole around the 50% growth inhibition target, resulting in less reproducible MIC determination (and less well-defined normal distributions for isavuconazole than for voriconazole). This may, at least in part, explain the higher degree of inter-laboratory variation previously observed for this species [2] . Finally, the MIC distributions for the two compounds against A. terreus mirrored one another with a modal MIC of 1 mg/L. In contrast, the modal MIC from the data set used to set EUCAST ECOFFs for isavuconazole was 0.5 mg/L and CLSI modal MICs are reported to be 0.25e0.5 mg/L [1, 23] . These discrepancies (± one dilution) are all within the expected variation for susceptibility testing, yet lead to interpretative disagreement when a restrictive endpoint is adopted. Of note, interlaboratory discrepancies in MIC testing of A. terreus in particular have previously been reported, but the underlying mechanism remain unclear [2] .
Our study has limitations. For Candida species, the truncation of the MIC distribution interfered with definitive MIC and wtUL determination, particularly for the normally azole-susceptible species. The discrepancy between wtULs for isavuconazole and voriconazole ECOFFs did result in some non-wt classification differences. For C. glabrata, the difference is most likely artificial and due to our strict definition of an wtUL, in combination with a truncated MIC interval. If we applied our strict definition of an wtUL on voriconazole, 15% of isolates would be non-wt for both compounds, suggesting comparable activity of the two.
One concern could be that we may have overlooked resistant A. fumigatus isolates, as confirmatory EUCAST AFST was only performed for isolates that grew on the screening agar (in which isavuconazole is not incorporated). We have EUCAST susceptibility tested one-quarter of all A. fumigatus isolates as they were originally screening positive, but only confirmed resistance in under one-quarter. Moreover, a recent multicentre study confirmed a specificity of 95%e100% (27th European Congress of Clinical Microbiology and Infectious Diseases, abstract P1750). On this background, we find it unlikely that the isavuconazole resistance rate was underestimated despite not performing EUCAST microdilution testing on all isolates. However, as isavuconazole was not licensed in our country in the years of isolate collection, it remains to be seen if isavuconazole mono-resistance mutations may occur once the compound is in clinical use.
In conclusion, the in vitro activity of voriconazole and isavuconazole is similar, with observed differences in Candida species being primarily due to methodological issues. This suggests that isavuconazole will be a promising new alternative in most cases where voriconazole is indicated, particularly in patients with invasive aspergillosis, and that susceptibility testing is important for clinical management.
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